@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_head { this: np:hasAssertion dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_assertion; np:hasProvenance dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_provenance; np:hasPublicationInfo dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_publicationInfo; a np:Nanopublication . dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_assertion a np:Assertion . dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_provenance a np:Provenance . dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_publicationInfo a np:PublicationInfo . } dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_assertion { miriam-gene:7855 a ncit:C16612 . lld:C0006826 a ncit:C7057 . dgn-gda:DGN781c175e815cf3d5ee3ca0a9044926bd sio:SIO_000628 miriam-gene:7855, lld:C0006826; a sio:SIO_001121 . } dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_provenance { dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_assertion dcterms:description "[The low cancer incidence in the epididymis may be due to factors present in the human epididymis that regulate this oncogenic Wnt/β-catenin pathway, including (i) 14 of 17 secreted pathway inhibitors, (ii) the majority of the micro-RNAs known to target this pathway, (iii) plasma membrane-associated E-cadherin and CEACAM1 that anchor β-catenin, preventing its availability for nuclear entry and oncogenic transcriptional activity, (iv) the recently identified membrane-located tumourigenesis inhibitors RNF43 and ZNRF3 that mediate the degradation of the Wnt receptor components Fzds and Lrp5/6 and (v) nuclear KLF4, which competes with TCF for β-catenin, limiting its transcriptional activity and stabilizing telomeres, thereby reducing mutation incidence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:23155044; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP932552.RAM9viLBiv_FsfCWeJUrhcBrM3klcbyE6vzyS05gOO9-E130_publicationInfo { this: dcterms:created "2014-10-02T12:41:31+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }